Etude : BOSTON 4 / BOSTON-4



ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.


Acronyme
Nom
Traitement
Type d'étude
MÀJ
Présentation de l'étude
Acronyme : BOSTON 4

Nom : BOSTON-4

Traitement :

Type d'étude : Hors ciblage moléculaire

Dernière MÀJ : 24/03/2020
Titre
Spécialité(s)
CIM10 - Localisation(s)
Informations principales
Titre : A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplant

Spécialité : Tissus lymphoïde, hématopoïétique et apparentés
Localisation : C96 - Tumeurs malignes des tissus lymphoïde, hématopoïétique et apparentés, autres et non précisées
Schéma
Phase
Stade
Ligne(s)
Informations complémentaires
Schéma : Brief Summary:
This is a Phase II prospective, multi-center, single-blind, randomized clinical trial of safety in the treatment of BOS 1 in adult recipients of an allogeneic hematopoetic stem cell transplant. Twenty-four patients are planned for enrollment. The clinical trial will be conducted in approximately 20 centers in Germany, France, and Spain. Patients will be randomly allocated 1:1:1 to receive either L-CsA (10 mg bid or 5 mg bid) plus Standard of Care, or liposomal placebo plus Standard of Care. Investigational Medicinal Product will be administered for up to 12 weeks

Arms:

Experimental: L-CsA 10 mg plus Standard of Care
Liposomal Cyclosporine A 10 mg bid for 12 weeks

Experimental: L-CsA 5 mg plus Standard of Care
Liposomal Cyclosporine A 5 mg bid for 12 weeks

Placebo Comparator: Liposomal Placebo plus Standard of Care
Liposomal Placebo 2.5 mL bid for 12 weeks

Phase : IIa

Stade : NA

NA
Informations libres de droit
Critères d'inclusion
Critères de non-inclusion
Informations libres de droit
Critères d'inclusion et de non-inclusion
Critères d'inclusion : Age >/= 18 years
Patient must have a history of allogeneic HSCT, regardless of source of stem cell or donor or indication for allogeneic HSCT
Documented diagnosis of chronic Graft versus Host Disease (cGvHD) in any organ other than the lung. If BOS is the only manifestation of cGvHD, lung biopsy must have been performed before entering the trial to confirm BOS diagnosis.
Confirmed diagnosis of BOS Score 1 [Jagasia et al. 2015] within > 6 months and < 3 years after allo-HSCT:

FEV1/FVC < 0.7 at Screening Visit AND Post-bronchodilator FEV1 >/= 60 and ≤ 79% predicted at Screening Visit AND

10% decline of FEV1 % predicted within 24 months prior to Screening Visit AND Absence of acute infection in the respiratory tract.
Patient must be capable of understanding the purposes and risks of the study, has given written informed consent, and agrees to comply with the study requirements.
Patient is capable of aerosol inhalation.
Women of childbearing potential must have a negative serum or urine pregnancy test at screening and at randomization visit.

Critères de non-inclusion : Active bacterial, viral (as confirmed by multiplex PCR) or fungal infection not successfully resolved at least 4 weeks prior to the Screening Visit.
Chronic renal dysfunction with serum creatinine >/= 2.5 mg/dL or need for renal dialysis.
Chronic hepatic dysfunction with serum total bilirubin > 5x upper limit of normal (ULN), transaminases > 5x ULN, or alkaline phosphatase > 5x ULN.
Evidence of relapse of the primary malignancy which warranted allogeneic bone marrow transplant.
Use of azithromycin within 4 weeks prior to Randomization (Visit 1).
Use of zafirlukast during the study period.
Chronic oxygen use or use of non-invasive ventilation.
Active smokers (i.e. any kind of inhaled nicotine consumption).
Pregnant women or women who are unwilling to use appropriate birth control to avoid pregnancy over the course of the clinical trial.
Women who are currently breastfeeding.
Known hypersensitivity to L-CsA or to cyclosporine A.
Patients who do not tolerate administration of inhaled bronchodilators (e.g., salbutamol).
Patients with life-expectancy of less than 6 months.
Treatments with other Investigational Medicinal Products (IMPs) or previous therapies within four weeks or five times half-life of the drug, whichever is longer prior to screening and during the study. Participation in registries, considering the before, is allowed.
Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary procedures.
Any co-existing medical condition that in the Investigator's judgment will substantially increase the risk associated with the patient's participation in the clinical trial.
Pre-scheduled hospitalizations, surgeries or interventions planned to be performed after obtaining Informed Consent for this study.
NCT
Promoteur
Coordonnateur
Informations relatives au promoteur
NCT :
NCT04107675
Promoteur :
Breath Therapeutics inc.
Type de sponsor : Industriel
Aldringenstraße 4 (2nd Floor) 80639 Munich, Germany -
00000 HORS FRANCE

Coordonnateur :
Dr Noreen R Henig
Centre investigateur
Investigateur
TEC / ARC / IDE
État
MÀJ
Informations relatives aux investigateurs
Centre investigateur :
Centre Henri Becquerel - Rue d'Amiens CS 11516 - Cedex 1 - 76000 ROUEN

Investigateur :
Dr E. LHUILLIER

TEC / ARC / IDE :
stéphanie SERIS
stephanie.seris@
chb.unicancer.fr
02.32.08.24.98

Statut de l'essai : OUVERT

MAJ : 24/03/2020